Table 1.
Patient characteristics
| Characteristic | All patients (N = 83) |
|---|---|
| Outcome—no. (%) | |
| Deceased | 70 (84) |
| Survive | 13 (16) |
| Sex—no. (%) | |
| Male | 46 (55) |
| Female | 37 (45) |
| Age at time of allogeneic HSCT—y | |
| Median (interquartile range) | 54 (47‐62) |
| Range | 18‐71 |
| Prognostic class at time of AML diagnosis—no. (%) | |
| Good risk | 3 (4) |
| Intermediate risk | 19 (23) |
| Poor risk | 35 (42) |
| Very poor risk | 26 (31) |
| WHO classification—no. (%) | |
| AML with recurrent genetic abnormalities | 33 (40) |
| AML with myelodysplasia‐related changes | 9 (11) |
| Therapy‐related myeloid neoplasms | 6 (7) |
| AML NOS | 32 (39) |
| Other | 3 (4) |
| HSCT donor—no. (%) | |
| MUD (10/10) | 53 (64) |
| SIB | 28 (34) |
| CB | 2 (2) |
| Conditioning regimen—no. (%) | |
| Myeloablative | 8 (10) |
| Reduced intensity | 71 (85) |
| FLAMSA | 4 (5) |
| Bone marrow blast count at time of relapse—% (N = 74) | |
| Median (interquartile range) | 25 (14‐52.25) |
| Range | 0†‐99 |
| Time between allogeneic HSCT and relapse—wk | |
| Median (interquartile range) | 21 (12‐32) |
| Range | 3‐187 |
| Very early vs late relapse—no. (%) | |
| Very early (<3 mo) | 23 (28) |
| Late (≥3 mo) | 60 (72) |
| Early vs late relapse—no. (%) | |
| Early (<6 mo) | 52 (63) |
| Late (≥6 mo) | 31 (37) |
| Intention to treat—no. (%) | |
| Curative | 50 (60) |
| Palliative (best supportive care) | 33 (40) |
†
Four patients had an isolated central nervous system relapse.